Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial.

24/05/2021

Leukemia

Authors: Hans Salwender, Ahmet Elmaagacli, Maximilian Merz, Kaya Miah, Axel Benner, Mathias Haenel, Christian Jehn, Elias K Mai, Uta Bertsch, Igor W Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Anna Jauch, Marc S Raab, Steffen P Luntz, Britta Besemer, Markus Munder, Peter Brossart, Stephan Fuhrmann, Hans-Walter Lindemann, Katja Weisel, Jan Duerig, Hartmut Goldschmidt